How could LabCorp's acquisition of prenatal testing affect Quest Diagnostics?
Quest Diagnostics may face increased competition from LabCorp's expanded prenatal testing portfolio. The acquisition of Myriad Genetics' Prenatal Health testing business by LabCorp significantly expands Labcorp's offerings in the reproductive genetics platform. This move strengthens Labcorp's competitive position within the molecular diagnostic testing market. As Labcorp and Quest Diagnostics are active competitors in the healthcare sector, this increased market strength for Labcorp could lead to greater competitive pressure on Quest Diagnostics' market share and service offerings.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Quest Diagnostics
-
Myriad Genetics announced it is selling its Prenatal Health testing business to LabCorp. The transaction includes tests such as Prequel®, Foresight®, SneakPeek®, and FirstGene®. LabCorp will acquire the business for $210 million in cash, plus the value of the inventory.
The full event1independent outlet -
By integrating Myriad's reproductive genetics platform and screening solutions, Labcorp enhances its capabilities in the prenatal testing market. Since Labcorp and Quest Diagnostics are known competitors in the medical research and diagnostic sector, this expansion increases the competitive intensity for both entities.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
medical research company
Everything about Quest Diagnostics
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Myriad Genetics sold its Prenatal Health testing business to Labcorp.manilatimes.net
- The Prenatal Health testing business includes the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests.manilatimes.net
- The transaction was for $210 million in cash, plus the value of the inventory.manilatimes.net
Why it matters
The prenatal testing market is a specialized segment of molecular diagnostics, and the acquisition allows Labcorp to immediately bolster its portfolio with established, recognized tests. For Quest Diagnostics, which operates in the same competitive space, the strengthening of a major rival like Labcorp requires a strategic response to maintain market share and pricing power.
This transaction is part of a broader trend of consolidation within the healthcare diagnostics industry, where large laboratory service providers are acquiring specialized testing capabilities. The ability of Labcorp to integrate Myriad's expertise and patient base could accelerate its growth strategy, putting pressure on other major players like Quest Diagnostics.
What we don't know yet
- How will Quest Diagnostics adjust its pricing or service offerings to counter Labcorp's expanded portfolio?
- What is the expected market share gain for Labcorp following the integration of the prenatal testing business?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- Applied DNA SciencesPossibleLabCorp's expanded diagnostic capacity may increase competitive pressure on Applied DNA Sciences
- FDAPossibleLabcorp's expanded prenatal testing portfolio may require FDA review
- MedicarePossibleIncreased prenatal testing volume could expand Medicare's utilization of lab services.
Reporting
- manilatimes.netOct 20
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.